文献速递消化系统肿瘤

Istiratumab联合白蛋白紫杉醇和吉西他滨一线治疗转移性胰腺癌的随机双盲安慰剂对照II期研究

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
PubMed 文献 · Ann Oncol · 2020-01-01

CARRIE研究是一项国际随机双盲安慰剂对照II期试验,评估IGF-1R/ErbB3双特异性抗体istiratumab联合标准化疗(吉西他滨/白蛋白紫杉醇)在初治转移性胰腺导管腺癌患者中的疗效。第二部分随机入组88例高血清游离IGF-1水平患者,结果显示istiratumab组中位无进展生存期(PFS)为3.6个月,对照组为7.3个月(HR=1.88,P=0.027),未能改善疗效。

要点

  • istiratumab联合标准化疗未改善高IGF-1水平转移性胰腺癌患者的PFS。
  • 高血清IGF-1水平相比非生物标志物选择的历史对照未显示不良预后。
  • 试验组低级别不良事件导致早期停药比例较高(39.5% vs 24.4%)。

核心结论

  • Istiratumab未能提高标准化疗在转移性胰腺癌患者中的疗效。

研究设计与样本

  • CARRIE为国际、随机、双盲、安慰剂对照II期研究,纳入初治转移性胰腺导管腺癌患者。
  • 第1部分评估10例患者的药代动力学和安全性;第2部分将高血清游离IGF-1水平患者按1:1随机接受istiratumab(2.8g静脉每2周)或安慰剂联合吉西他滨/白蛋白紫杉醇(批准剂量方案)。
  • 共筛查317例患者,第2部分随机88例(试验组n=43,对照组n=45)。

主要发现

  • 高IGF-1队列中,试验组与对照组中位PFS分别为3.6个月和7.3个月(HR=1.88,P=0.027)。
  • 高IGF-1/HRG+亚组(n=44)中,中位PFS分别为4.1个月和7.3个月(HR=1.39,P=0.42)。
  • 总体人群的中位OS和ORR在两组间相似。
  • 严重不良事件或≥3级不良事件无显著差异,但试验组低级别不良事件导致早期停药的比例较高(39.5% vs 24.4%)。

临床怎么用

  • 不推荐在转移性胰腺癌中常规联合istiratumab与吉西他滨/白蛋白紫杉醇。
  • 高血清IGF-1水平不应被视为不良预后因素用于临床决策。

局限性

  • II期研究样本量有限(随机88例),结论需进一步验证。
  • 高IGF-1/HRG+亚组样本量小(n=44),统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical data suggest that dual blockade of the insulin-like growth factor-1 receptor (IGF-1R) and HER3 pathways has superior activity to IGF-1R blockade alone in pancreatic ductal adenocarcinoma (PDAC). We tested whether istiratumab, an IGF-1R- and ErbB3-bispecific antibody, can enhance the efficacy of standard of care (SOC) chemotherapy in patients with metastatic PDAC selected for high IGF-1 serum levels. PATIENTS AND METHODS: CARRIE was an international, randomized, double-blind, placebo-controlled phase II study for patients with previously untreated metastatic PDAC. In part 1, 10 patients were evaluated for pharmacokinetics and safety. In part 2, patients with high free serum IGF-1 levels were randomized 1 : 1 to receive either istiratumab [2.8 g intravenously (i.v.) every 2 weeks] or placebo combined with gemcitabine/nab-paclitaxel at approved dose schedule. The co-primary endpoints were progression-free survival (PFS) in patients with high IGF-1 levels and PFS in patients with both high serum IGF-1 levels and heregulin (HRG)+ tumors. Key secondary endpoints were overall survival (OS), objective response rate (ORR) by RECIST v.1.1, and adverse events (AEs) rate. RESULTS: A total of 317 patients were screened, with 88 patients randomized in part 2 (experimental arm n = 43; control n = 45). In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027]. In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42). Median OS and ORR for the overall population were similar between two arms. No significant difference in serious or grade ≥3 AEs was observed, although low-grade AEs leading to early discontinuation were higher in the experimental (39.5%) versus control arm (24.4%). CONCLUSIONS: Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting. High serum IGF-1 levels did not appear to be an adverse prognostic factor when compared with non-biomarker-selected historic controls. CLINICAL TRIAL REGISTRATION NUMBERS: ClinicalTrials.gov: NCT02399137; EUDRA CT: 2014-004572-34.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kundranda M, Gracian AC, Zafar SF, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020. PMID: 31912800. doi:10.1016/j.annonc.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。